

<b>National Imaging Associates, Inc. *</b>	
<b>Clinical Guideline: NEUTRON BEAM THERAPY (NBT)</b>	<b>Original Date: November 2013</b>
<b>CPT Codes: 77422, 77423</b>	<b>Last Revised Date: January 2022</b>
<b>Guideline Number: NIA_CG_229</b>	<b>Implementation Date: January 2023</b>

## INDICATIONS FOR NEUTRON BEAM THERAPY

- Neutron beam treatment is indicated for salivary gland cancers that are inoperable, recurrent, or are resected with gross residual disease or positive margins.<sup>1</sup>
- Other uses of Neutron Beam Therapy are considered investigational and therefore are not approved because its effectiveness for these indications has not been established.

---

## BACKGROUND

Neutron Beam Therapy (NBT) is a type of radiation treatment that uses a particle accelerator so is not readily available in most of the country. Protons from the accelerator create a neutron beam that attacks cancer cells with more power than conventional radiation therapy. Neutrons are much heavier than photons, thus appear to be more effective in destroying very dense tumors. With neutron beam treatment, the risk of side effects on healthy tissue near the cancer site is greater, requiring equipment to precisely focus the beam and block exposure to any surrounding tissue. Currently, both the availability and the criteria for use are very limited.

### Overview:

NBT has been employed mainly for the treatment of the salivary gland cancers. It has also been used to treat other malignancies such as soft tissue sarcoma, lung, pancreatic, colon, kidney, and prostate cancers. Nevertheless, NBT has not gained wide acceptance because of the clinical difficulty in generating neutron particles and limited publications.

The safety and efficacy of neutron beam radiation therapy has not been established in the published medical literature. Complication rates were increased for NBT compared to other forms of external beam radiation therapy, and questions remain with regard to patient selection criteria, technical parameters, and comparative efficacy to other treatment modalities.

---

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

**POLICY HISTORY**

<b>Date</b>	<b>Summary</b>
January 2022	No Changes
February 2021	No Changes
February 2020	No Changes
February 2019	Added and updated references

## REFERENCES

1. American Cancer Society. Radiation Therapy for Salivary Gland Cancer. Updated September 28, 2017. Accessed December 10, 2021. <https://www.cancer.org/cancer/salivary-gland-cancer/treating/radiation-therapy.html>

## ADDITIONAL RESOURCES

1. Airoidi M, Cortesina G, Giordano C, et al. Update and perspectives on non-surgical treatment of salivary gland malignancies. *Acta Otorhinolaryngol Ital*. Oct 2003;23(5):368-76.
2. American Society of Clinical Oncology. Salivary Gland Cancer: Types of Treatment. Updated May 2020. Accessed December 10, 2021. <https://www.cancer.net/cancer-types/salivary-gland-cancer/types-treatment>
3. Chou RH, Wilder RB, Wong MS, Forster KM. Recent advances in radiotherapy for head and neck cancers. *Ear Nose Throat J*. Oct 2001;80(10):704-7, 711-4, 716 passim.
4. Davis C, Sikes J, Namaranian P, Laramore G, Dillon JK. Neutron Beam Radiation Therapy: An Overview of Treatment and Oral Complications When Treating Salivary Gland Malignancies. *J Oral Maxillofac Surg*. Apr 2016;74(4):830-5. doi:10.1016/j.joms.2015.10.014
5. Day TA, Deveikis J, Gillespie MB, et al. Salivary gland neoplasms. *Curr Treat Options Oncol*. Feb 2004;5(1):11-26. doi:10.1007/s11864-004-0002-x
6. Eng TY, Thomas CR, Herman TS. Primary radiation therapy for localized prostate cancer. *Urol Oncol*. Nov-Dec 2002;7(6):239-57. doi:10.1016/s1078-1439(02)00198-9
7. Engenhart-Cabillic R, Debus J, Prott FJ, et al. Use of neutron therapy in the management of locally advanced nonresectable primary or recurrent rectal cancer. *Recent Results Cancer Res*. 1998;150:113-24. doi:10.1007/978-3-642-78774-4\_6
8. Horizon Scanning Technology Prioritising Summary: Boron neutron capture therapy for cancer treatment. Australian Government Department of Health and Ageing; Australia and New Zealand Horizon Scanning Network (ANZHSN). Updated October 2007. Accessed December 10, 2021. [http://www.horizonscanning.gov.au/internet/horizon/publishing.nsf/Content/6B81AEB3E7EE0001CA2575AD0080F344/\\$File/Vol%2018%20-%20boron%20neutron%20capture%20therapy.pdf](http://www.horizonscanning.gov.au/internet/horizon/publishing.nsf/Content/6B81AEB3E7EE0001CA2575AD0080F344/$File/Vol%2018%20-%20boron%20neutron%20capture%20therapy.pdf)
9. Huber PE, Debus J, Latz D, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? *Radiother Oncol*. May 2001;59(2):161-7. doi:10.1016/s0167-8140(00)00273-5
10. Kankaanranta L, Seppälä T, Koivunoro H, et al. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. *Int J Radiat Oncol Biol Phys*. Jun 1 2011;80(2):369-76. doi:10.1016/j.ijrobp.2010.02.031
11. Lindsley KL, Cho P, Stelzer KJ, et al. Fast neutrons in prostatic adenocarcinomas: worldwide clinical experience. *Recent Results Cancer Res*. 1998;150:125-36. doi:10.1007/978-3-642-78774-4\_7
12. Murray PM. Soft tissue sarcoma of the upper extremity. *Hand Clin*. Aug 2004;20(3):325-33, vii. doi:10.1016/j.hcl.2004.03.007
13. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers Version 1.2022. National Comprehensive Cancer Network (NCCN). Updated December 8, 2021. Accessed December 10, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)
14. Strander H, Turesson I, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. *Acta Oncol*. 2003;42(5-6):516-31. doi:10.1080/02841860310014732

**Reviewed / Approved by NIA Clinical Guideline Committee**

## GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.